APA (7th ed.) Citation

A, P., JVR, M., L, F., K, L., N, L., S, B., . . . G, D. (2025). Safety and immunogenicity of a tetravalent dengue vaccine (CYD-TDV) in HIV-positive adults aged 18-50 years in Brazil: Results from a phase II, randomized, observer-blind, placebo-controlled trial. Human vaccines & immunotherapeutics, 21(1), 2582237. https://doi.org/10.1080/21645515.2025.2582237

Chicago Style (17th ed.) Citation

A, Perroud, et al. "Safety and Immunogenicity of a Tetravalent Dengue Vaccine (CYD-TDV) in HIV-positive Adults Aged 18-50 Years in Brazil: Results from a Phase II, Randomized, Observer-blind, Placebo-controlled Trial." Human Vaccines & Immunotherapeutics 21, no. 1 (2025): 2582237. https://doi.org/10.1080/21645515.2025.2582237.

MLA (9th ed.) Citation

A, Perroud, et al. "Safety and Immunogenicity of a Tetravalent Dengue Vaccine (CYD-TDV) in HIV-positive Adults Aged 18-50 Years in Brazil: Results from a Phase II, Randomized, Observer-blind, Placebo-controlled Trial." Human Vaccines & Immunotherapeutics, vol. 21, no. 1, 2025, p. 2582237, https://doi.org/10.1080/21645515.2025.2582237.